{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:15:24Z","timestamp":1767143724481,"version":"build-2238731810"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The goal of our study was to examine the long-term effect of vigabatrin (VGB), a\n                      <jats:italic>\u03b3<\/jats:italic>\n                      -aminobutyric acid aminotransferase (GABA-AT) inhibitor on clonazepam (CLO), ethosuximide (ETX) and valproate (VPA) anticonvulsive activity against pentylenetetrazole (PTZ)-induced seizures in mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      VGB was administered for 3 and 7\u00a0days. Convulsions were evoked by PTZ at its CD97 (99\u00a0mg\/kg). The influence of CLO, ETX and VPA alone or in combination with VGB on motor performance and long-term memory was analyzed.\n                      <jats:italic>\u03b3<\/jats:italic>\n                      -aminobutyric acid (GABA) concentration in mice brain and plasma as well as glutamate decarboxylase (GAD) activity was measured.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 3\u00a0days of treatment, VGB in doses up to 500\u00a0mg\/kg increased PTZ-induced seizure threshold, whereas after 7\u00a0days VGB (at the dose of 125\u00a0mg\/kg) inhibited clonic seizures in experimental mice. 7\u00a0days of VGB administration did not change the protective effect of CLO, ETX and VPA against PTZ-induced seizures. 7\u00a0days of VGB treatment at a subthreshold dose of 75\u00a0mg\/kg decreased TD50 of ETX and CLO in the chimney test, but did not affect TD50 value for VPA. 7\u00a0days of VGB administration in combination with AEDs did not affect long-term memory in mice. VGB after 3\u00a0days or 7\u00a0days of administration increased brain GABA concentration. GAD activity was decreased after 3 and 7\u00a0days of VGB administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The presented results confirm anticonvulsive activity of VGB through GABA metabolism alteration and suggest care when combining VGB with ETX or CLO in the therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43440-019-00037-6","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T11:47:20Z","timestamp":1583236040000},"page":"322-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term vigabatrin treatment modifies pentylenetetrazole-induced seizures in mice: focused on GABA brain concentration"],"prefix":"10.1007","volume":"72","author":[{"given":"Mariusz J.","family":"\u015awi\u0105der","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"\u015awi\u0105der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela","family":"Zakrocka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Krzy\u017canowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Wr\u00f3bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarogniew J.","family":"\u0141uszczki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanis\u0142aw J.","family":"Czuczwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"37_CR1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fneur.2017.00301","volume":"8","author":"F Tang","year":"2017","unstructured":"Tang F, Hartz AMS, Bauer B. Drug-resistant epilepsy: multiple hypotheses few answers. Front Neurol. 2017;8:301.","journal-title":"Front Neurol"},{"issue":"6","key":"37_CR2","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4103\/ijmr.IJMR_548_17","volume":"145","author":"SN Duble","year":"2017","unstructured":"Duble SN, Thomas SV. Sudden unexpected death in epilepsy. Indian J Med Res. 2017;145(6):738\u201345.","journal-title":"Indian J Med Res"},{"issue":"19","key":"37_CR3","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.4045\/tidsskr.08.0701","volume":"129","author":"KO Nakken","year":"2009","unstructured":"Nakken KO, Taub\u00f8ll E. Drug-resistant epilepsy. Tidsskr Nor Laegeforen. 2009;129(19):1986\u20139.","journal-title":"Tidsskr Nor Laegeforen"},{"key":"37_CR4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eplepsyres.2017.02.020","volume":"132","author":"J M\u00e4kinen","year":"2017","unstructured":"M\u00e4kinen J, Rainesalo S, Raitanen J, Peltola J. The effect of newer antiepileptic drugs in combination therapy. Epilepsy Res. 2017;132:15\u201320.","journal-title":"Epilepsy Res"},{"issue":"3","key":"37_CR5","first-page":"317","volume":"145","author":"R Joshi","year":"2017","unstructured":"Joshi R, Tripathi M, Gupta P, Gulati S, Gupta YK. Adverse effects & drug load of antiepileptic drugs in patients with epilepsy: monotherapy versus polytherapy. Indian J Med Res. 2017;145(3):317\u201326.","journal-title":"Indian J Med Res"},{"key":"37_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8621-x","author":"Q Hu","year":"2017","unstructured":"Hu Q, Zhang F, Teng W, Hao F, Zhang J, Yin M, Wang N. Efficacy and safety of antiepileptic drugs for refractory partial-onset epilepsy: a network meta-analysis. J Neurol. 2017. https:\/\/doi.org\/10.1007\/s00415-017-8621-x.","journal-title":"J Neurol"},{"issue":"4441","key":"37_CR7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1126\/science.6768130","volume":"208","author":"K Gale","year":"1980","unstructured":"Gale K, Iadarola MJ. Seizure protection and increased nerve-terminal GABA: delayed effects of GABA transaminase inhibition. Science. 1980;208(4441):288\u201391.","journal-title":"Science"},{"key":"37_CR8","first-page":"S11","volume":"Suppl 2","author":"E Ben-Menachem","year":"1991","unstructured":"Ben-Menachem E, Persson LI, Mumford J, Haegele KD, Huebert N. Effect of long-term vigabatrin therapy on selected neurotransmitter concentrations in cerebrospinal fluid. J Child Neurol. 1991;Suppl 2:S11\u20136.","journal-title":"J Child Neurol"},{"issue":"1","key":"37_CR9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0014-2999(90)90498-U","volume":"182","author":"Z Liu","year":"1990","unstructured":"Liu Z, Seiler N, Marescaux C, Depaulis A, Vergnes M. Potentiation of gamma-vinyl GABA (vigabatrin) effects by glycine. Eur J Pharmacol. 1990;182(1):109\u201315.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"37_CR10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1528-1157.1991.tb05251.x","volume":"32","author":"T Halonen","year":"1991","unstructured":"Halonen T, Pitk\u00e4nen A, Saano V, Riekkinen PJ. Effects of vigabatrin (gamma-vinyl GABA) on neurotransmission-related amino acids and on GABA and benzodiazepine receptor binding in rats. Epilepsia. 1991;32(2):242\u20139.","journal-title":"Epilepsia"},{"issue":"7","key":"37_CR11","first-page":"713","volume":"48","author":"S Engelborghs","year":"1998","unstructured":"Engelborghs S, Pickut BA, D\u2019Hooge R, Wiechert P, Haegele K, De Deyn PP. Behavioral effects of vigabatrin correlated with whole brain gamma-aminobutyric acid metabolism in audiogenic sensitive rats. Arzneimittelforschung. 1998;48(7):713\u20136.","journal-title":"Arzneimittelforschung"},{"issue":"2","key":"37_CR12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0006-8993(86)90484-1","volume":"370","author":"L Turski","year":"1986","unstructured":"Turski L, Cavalheiro EA, Schwarz M, Turski WA, De Moraes Mello LE, Bortolotto ZA, Klockgether T, Sontag KH. Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra. Brain Res. 1986;370(2):294\u2013309.","journal-title":"Brain Res"},{"issue":"3","key":"37_CR13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0014-4886(87)90304-9","volume":"95","author":"W L\u00f6scher","year":"1987","unstructured":"L\u00f6scher W, Czuczwar SJ, J\u00e4ckel R, Schwarz M. Effect of microinjections of gamma-vinyl GABA or isoniazid into substantia nigra on the development of amygdala kindling in rats. Exp Neurol. 1987;95(3):622\u201338.","journal-title":"Exp Neurol"},{"issue":"1\u20132","key":"37_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-8993(91)91262-Y","volume":"545","author":"Z Liu","year":"1991","unstructured":"Liu Z, Vergnes M, Depaulis A, Marescaux C. Evidence for a critical role of GABAergic transmission within the thalamus in the genesis and control of absence seizures in the rat. Brain Res. 1991;545(1\u20132):1\u20137.","journal-title":"Brain Res"},{"issue":"4","key":"37_CR15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1006\/phrs.1993.1134","volume":"28","author":"U Sayin","year":"1993","unstructured":"Sayin U, Cengiz S, Altug T. Vigabatrin as an anticonvulsant against pentylenetetrazol seizures. Pharmacol Res. 1993;28(4):325\u201331.","journal-title":"Pharmacol Res"},{"issue":"1","key":"37_CR16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0304-3940(95)11766-P","volume":"195","author":"T Halonen","year":"1995","unstructured":"Halonen T, Miettinen R, Toppinen A, Tuunanen J, Kotti T, Riekkinen PJ Sr. Vigabatrin protects against kainic acid-induced neuronal damage in the rat hippocampus. Neurosci Lett. 1995;195(1):13\u20136.","journal-title":"Neurosci Lett"},{"issue":"Suppl 1","key":"37_CR17","first-page":"S36","volume":"9","author":"H Kubov\u00e1","year":"2007","unstructured":"Kubov\u00e1 H, Mares P. Hypoxia-induced changes of seizure susceptibility in immature rats are modified by vigabatrin. Epileptic Disord. 2007;9(Suppl 1):S36\u201343.","journal-title":"Epileptic Disord"},{"issue":"2","key":"37_CR18","doi-asserted-by":"crossref","first-page":"e57445","DOI":"10.1371\/journal.pone.0057445","volume":"8","author":"B Zhang","year":"2013","unstructured":"Zhang B, McDaniel SS, Rensing NR, Wong M. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. PLoS ONE. 2013;8(2):e57445.","journal-title":"PLoS ONE"},{"key":"37_CR19","doi-asserted-by":"crossref","unstructured":"Hemming K, Maguire MJ, Hutton JL, Marson AG (2008) Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev (3):CD007302.","DOI":"10.1002\/14651858.CD007302"},{"issue":"2\u20133","key":"37_CR20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0920-1211(99)00082-0","volume":"38","author":"I Jambaqu\u00e9","year":"2000","unstructured":"Jambaqu\u00e9 I, Chiron C, Dumas C, Mumford J, Dulac O. Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. Epilepsy Res. 2000;38(2\u20133):151\u201360.","journal-title":"Epilepsy Res"},{"issue":"1","key":"37_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.1995.tb05834.x","volume":"91","author":"MG Marciani","year":"1995","unstructured":"Marciani MG, Maschio M, Spanedda F, Iani C, Gigli GL, Bernardi G. Development of myoclonus in patients with partial epilepsy during treatment with vigabatrin: an electroencephalographic study. Acta Neurol Scand. 1995;91(1):1\u20135.","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"37_CR22","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2165\/00003495-199141060-00007","volume":"41","author":"SM Grant","year":"1991","unstructured":"Grant SM, Heel RC. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs. 1991;41(6):889\u2013926.","journal-title":"Drugs"},{"issue":"5","key":"37_CR23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/jnnp.55.5.413","volume":"55","author":"N Turjanski","year":"1992","unstructured":"Turjanski N, Lees AJ. Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1992;55(5):413.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"37_CR24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/jnnp.54.5.435","volume":"54","author":"JW Sander","year":"1991","unstructured":"Sander JW, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry. 1991;54(5):435\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"37_CR25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0404.2011.01603.x","volume":"Suppl 192","author":"JM Pellock","year":"2011","unstructured":"Pellock JM. Balancing clinical benefits of vigabatrin with its associated risk of vision loss. Acta Neurol Scand. 2011;Suppl 192:83\u201391.","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"37_CR26","first-page":"363","volume":"55","author":"M Swiader","year":"2003","unstructured":"Swiader M, \u0141uszczki J, Wielosz M, Czuczwar SJ. Influence of vigabatrin, a novel antiepileptic drug, on the anticonvulsant activity of conventional antiepileptics in pentetrazole-induced seizures in mice. Pol J Pharmacol. 2003;55(3):363\u201370.","journal-title":"Pol J Pharmacol"},{"issue":"10","key":"37_CR27","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/0028-3908(90)90145-H","volume":"29","author":"SJ Czuczwar","year":"1990","unstructured":"Czuczwar SJ, Ma\u0142ek U, Kleinrok Z. Influence of calcium channel inhibitors upon the anticonvulsant efficacy of common antiepileptics against pentylenetetrazol-induced convulsions in mice. Neuropharmacology. 1990;29(10):943\u20138.","journal-title":"Neuropharmacology"},{"issue":"7","key":"37_CR28","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/BF01273360","volume":"103","author":"M Gasior","year":"1996","unstructured":"Gasior M, Kami\u0144ski R, Brudniak T, Kleinrok Z, Czuczwar SJ. Influence of nicardipine, nimodipine and flunarizine on the anticonvulsant efficacy of antiepileptics against pentylenetetrazol in mice. J Neural Transm (Vienna). 1996;103(7):819\u201331.","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"37_CR29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF01243421","volume":"72","author":"R Bernasconi","year":"1988","unstructured":"Bernasconi R, Klein M, Martin P, Christen P, Hafner T, Portet C, Schmutz M. Gamma-vinyl GABA: comparison of neurochemical and anticonvulsant effects in mice. J Neural Transm. 1988;72(3):213\u201333.","journal-title":"J Neural Transm"},{"key":"37_CR30","first-page":"81","volume":"3","author":"JR Boissier","year":"1960","unstructured":"Boissier JR, Tardy J, Diverres JC. Une nouvelle m\u00e9thode simple pour explorer l\u2019action \u2018tranquillisante\u2019: le test de la chemin\u00e9e. Med. Exp. 1960;3:81\u20134.","journal-title":"Med. Exp"},{"issue":"6073","key":"37_CR31","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/321864a0","volume":"321","author":"P Venault","year":"1986","unstructured":"Venault P, Chapouthier G, de Carvalho LP, Simiand J, Morre M, Dodd RH, Rossier J. Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature. 1986;321(6073):864\u20136.","journal-title":"Nature"},{"issue":"5","key":"37_CR32","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/0168-0102(89)90009-6","volume":"6","author":"SJ Czuczwar","year":"1989","unstructured":"Czuczwar SJ, Janusz W, Szczepanik B, Wamil A, Kleinrok Z. Effect of aminophylline upon the protective activity of common antiepileptic drugs and their plasma levels in mice. Neurosci Res. 1989;6(5):470\u20134.","journal-title":"Neurosci Res"},{"issue":"2","key":"37_CR33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.pharep.2015.09.009","volume":"68","author":"MJ \u015awi\u0105der","year":"2016","unstructured":"\u015awi\u0105der MJ, Barczy\u0144ski B, Tomaszewski M, \u015awi\u0105der K, Czuczwar SJ. The effects of cimetidine chronic treatment on conventional antiepileptic drugs in mice. Pharmacol Rep. 2016;68(2):283\u20138.","journal-title":"Pharmacol Rep"},{"issue":"1","key":"37_CR34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1471-4159.1958.tb12604.x","volume":"3","author":"IP Lowe","year":"1958","unstructured":"Lowe IP, Robins E, Eyerman GS. The fluorometric measurement of glutamic decarboxylase and its distribution in brain. J Neurochem. 1958;3(1):8\u201318.","journal-title":"J Neurochem"},{"issue":"13","key":"37_CR35","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/0006-2952(74)90188-9","volume":"23","author":"I Sutton","year":"1974","unstructured":"Sutton I, Simmonds MA. Effects of acute and chronic pentobarbitone on the gamma-aminobutyric acid system in rat brain. Biochem Pharmacol. 1974;23(13):1801\u20138.","journal-title":"Biochem Pharmacol"},{"key":"37_CR36","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0006-2952(64)90008-5","volume":"13","author":"T Uchida","year":"1964","unstructured":"Uchida T, O\u2019Brien RD. The effects of hydrazines on rat brain 5-hydroxytryptamine, norepinephrine, and gamma-aminobutyric acid. Biochem Pharmacol. 1964;13:725\u201330.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"37_CR37","first-page":"99","volume":"96","author":"JT Litchfield Jr","year":"1949","unstructured":"Litchfield JT Jr., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949;96(2):99\u2013113.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"37_CR38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0920-1211(87)90014-3","volume":"1","author":"S Piredda","year":"1987","unstructured":"Piredda S, Pavlick M, Gale K. Anticonvulsant effects of GABA elevation in the deep prepiriform cortex. Epilepsy Res. 1987;1(2):102\u20136.","journal-title":"Epilepsy Res"},{"key":"37_CR39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neuint.2019.02.015","volume":"125","author":"DC Walters","year":"2019","unstructured":"Walters DC, Arning E, Bottiglieri T, Jansen EEW, Salomons GS, Brown MN, Schmidt MA, Ainslie GR, Roullet JB, Gibson KM. Metabolomic analyses of vigabatrin (VGB)-treated mice: GABA-transaminase inhibition significantly alters amino acid profiles in murine neural and non-neural tissues. Neurochem Int. 2019;125:151\u201362.","journal-title":"Neurochem Int"},{"issue":"11","key":"37_CR40","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/0006-2952(81)90298-7","volume":"30","author":"AS Abdul-Ghani","year":"1981","unstructured":"Abdul-Ghani AS, Norris PJ, Smith CC, Bradford HF. Effects of gamma-acetylenic GABA and gamma-vinyl GABA on synaptosomal release and uptake of GABA. Biochem Pharmacol. 1981;30(11):1203\u20139.","journal-title":"Biochem Pharmacol"},{"issue":"1\u20133","key":"37_CR41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejphar.2008.07.051","volume":"595","author":"JJ Luszczki","year":"2008","unstructured":"Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy. Eur J Pharmacol. 2008;595(1\u20133):13\u201321.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"37_CR42","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.pnpbp.2006.11.020","volume":"31","author":"JJ Luszczki","year":"2007","unstructured":"Luszczki JJ, Czuczwar SJ. Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):529\u201338.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"37_CR43","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/sj.npp.1300602","volume":"30","author":"JJ Luszczki","year":"2005","unstructured":"Luszczki JJ, Wojcik-Cwikla J, Andres MM, Czuczwar SJ. Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology. 2005;30(5):958\u201373.","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"37_CR44","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/epi.13802","volume":"58","author":"PN Patsalos","year":"2017","unstructured":"Patsalos PN, Zugman M, Lake C, James A, Ratnaraj N, Sander JW. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations. Epilepsia. 2017;58(7):1234\u201343.","journal-title":"Epilepsia"},{"issue":"6","key":"37_CR45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00003088-199630060-00001","volume":"30","author":"RD Elwes","year":"1996","unstructured":"Elwes RD, Binnie CD. Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin Pharmacokinet. 1996;30(6):403\u201315.","journal-title":"Clin Pharmacokinet"},{"issue":"1\u20132","key":"37_CR46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0920-1211(01)00299-6","volume":"47","author":"V Andr\u00e9","year":"2001","unstructured":"Andr\u00e9 V, Ferrandon A, Marescaux C, Nehlig A. Vigabatrin protects against hippocampal damage but is not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy. Epilepsy Res. 2001;47(1\u20132):99\u2013117.","journal-title":"Epilepsy Res"},{"issue":"5","key":"37_CR47","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.phrs.2004.12.006","volume":"51","author":"A Cuadrado","year":"2005","unstructured":"Cuadrado A, Armijo JA. Beneficial interaction between vigabatrin and valproate against seizures induced by pentylenetetrazole in mice. Pharmacol Res. 2005;51(5):489\u201396.","journal-title":"Pharmacol Res"},{"key":"37_CR48","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nbd.2016.03.012","volume":"91","author":"L Gey","year":"2016","unstructured":"Gey L, Gernert M, L\u00f6scher W. Continuous bilateral infusion of vigabatrin into the subthalamic nucleus: effects on seizure threshold and GABA metabolism in two rat models. Neurobiol Dis. 2016;91:194\u2013208.","journal-title":"Neurobiol Dis"},{"issue":"10","key":"37_CR49","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/0006-2952(92)90173-G","volume":"43","author":"EM Valdiz\u00e1n","year":"1992","unstructured":"Valdiz\u00e1n EM, Armijo JA. Effects of single and multiple increasing doses of vigabatrin on brain GABA metabolism and correlation with vigabatrin plasma concentration. Biochem Pharmacol. 1992;43(10):2143\u201350.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"37_CR50","first-page":"508","volume":"238","author":"JF Cubells","year":"1986","unstructured":"Cubells JF, Blanchard JS, Smith DM, Makman MH. In vivo action of enzyme-activated irreversible inhibitors of glutamic acid decarboxylase and gamma-aminobutyric acid transaminase in retina vs. brain. J Pharmacol Exp Ther. 1986;238(2):508\u201314.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"37_CR51","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1471-4159.1992.tb09291.x","volume":"58","author":"K Rimvall","year":"1992","unstructured":"Rimvall K, Martin DL. Increased intracellular gamma-aminobutyric acid selectively lowers the level of the larger of two glutamate decarboxylase proteins in cultured GABAergic neurons from rat cerebral cortex. J Neurochem. 1992;58(1):158\u201366.","journal-title":"J Neurochem"}],"updated-by":[{"DOI":"10.1007\/s43440-020-00065-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000}}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-019-00037-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s43440-019-00037-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-019-00037-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T19:35:03Z","timestamp":1608320103000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s43440-019-00037-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["37"],"URL":"https:\/\/doi.org\/10.1007\/s43440-019-00037-6","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,20]]},"assertion":[{"value":"18 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Long-term vigabatrin treatment modifies pentylenetetrazole-induced seizures in mice: focused on GABA brain concentration.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"On behalf all co-authors I would like to confirm that there are no known conflicts of interest\nassociated with this publication and there has been no significant financial support for this work that could have influenced its outcome.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}